TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11697427

Group type: EXPERIMENTAL
Intervention: Multidisciplinary behavioural treatment
Number of subjects: 27

Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 27
Study: 9803573

Group type: EXPERIMENTAL
Intervention: Self-help programme for climacteric and menopause, consisting of 10 weekly hour-long sessions including body movement exercises, relaxation, and group discussions.
Number of subjects: 106

Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 106
Study: 7634447

Group type: EXPERIMENTAL
Intervention: Upright stress test
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Supine bicycle stress test
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Transesophageal atrial pacing
Number of subjects: 9
Study: 2148360

Group type: EXPERIMENTAL
Intervention: High-dosage phenobarbital and cefotaxime
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Cefotaxime and phenobarbital combination
Number of subjects: 49
Study: 402325

Group type: EXPERIMENTAL
Intervention: 2% Carbocain with adrenaline 1:200,000
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 3% Citanest with Octapressin 0.03 iu/mul
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 3% Carbocain Dental
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 2% Xylocain with adrenaline 1:80,000
Number of subjects: 9
Study: 31352066

Group type: EXPERIMENTAL
Intervention: Hysteroscopic morcellation
Number of subjects: 86

Group type: COMPARATOR
Intervention: Loop resection
Number of subjects: 86
Study: 30469099

Group type: EXPERIMENTAL
Intervention: Parent-oriented alcohol prevention program 'Effekt' (intervention group)
Number of subjects: 985

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 985
Study: 28779928

Group type: EXPERIMENTAL
Intervention: SilAtro‐5‐90 in addition to standard symptomatic treatment
Number of subjects: 256

Group type: COMPARATOR
Intervention: Standard treatment only
Number of subjects: 256
Study: 26000670

Group type: EXPERIMENTAL
Intervention: Intravenous parecoxib
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 24262397

Group type: EXPERIMENTAL
Intervention: Sugar-free (xylitol) chewing gum
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sugared chewing gum
Number of subjects: 30
Study: 21739700

Group type: EXPERIMENTAL
Intervention: Electroacupuncture compound anesthesia (Sibai ST 2, Xiaguan ST 7, Hegu LI 4, Zhigou TE 6 on left side; routine local anesthesia on right side)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Routine local anesthesia (both sides)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Electroacupuncture compound anesthesia
Number of subjects: 61

Group type: COMPARATOR
Intervention: Routine local anesthesia
Number of subjects: 61
Study: 19454915

Group type: EXPERIMENTAL
Intervention: Family Spirit intervention (25 visits)
Number of subjects: 167

Group type: COMPARATOR
Intervention: Breast-feeding/nutrition education intervention (23 visits)
Number of subjects: 167
Study: 16713542

Group type: EXPERIMENTAL
Intervention: Anterior 90 degrees fundoplication
Number of subjects: 79

Group type: COMPARATOR
Intervention: Nissen fundoplication
Number of subjects: 79

Group type: COMPARATOR
Intervention: Both procedures
Number of subjects: 79
Study: 12495686

Group type: EXPERIMENTAL
Intervention: PMX-F treatment (N=15)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Teicoplanin treatment (N=15)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: PMX-F and teicoplanin in combination (N=20)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional therapy (N=10)
Number of subjects: 60
Study: 10596307

Group type: EXPERIMENTAL
Intervention: Untreated hypertensive group
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normotensive group
Number of subjects: 60
Study: 8729305

Group type: EXPERIMENTAL
Intervention: Preoperative autologous donation (PAD)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Preoperative acute normovolaemic haemodilution with erythrocytapheresis (erythro)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Intraoperative normovolaemic haemodilution (haemo)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Intraoperative blood loss in erythro group
Number of subjects: 45

Group type: COMPARATOR
Intervention: Correlation between haematocrit at d-1 and intraoperative bleeding
Number of subjects: 45
Study: 1859070

Group type: EXPERIMENTAL
Intervention: Mouthpiece and mask (MM)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Mask only (M)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Warm (34 degrees C), humidified air
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Topical application of 4% lidocaine to the oral mucosa
Number of subjects: 10
Study: 6615957

Group type: EXPERIMENTAL
Intervention: 200 msec stimulus interval
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 500 msec stimulus interval
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 4.5 sec preparatory interval
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 2 sec preparatory interval
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Meaningful stimuli
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Early occurring stimuli
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Late occurring stimuli
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Unattended stimuli
Number of subjects: 14
Study: 3925887

Group type: EXPERIMENTAL
Intervention: Bestatin combined with Mitomycin‐C, FT‐207
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not given Bestatin)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bestatin
Number of subjects: 0
Study: 31187126

Group type: EXPERIMENTAL
Intervention: Organized outreach using fecal immunochemical tests (FITs)
Number of subjects: 10820

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 10820
Study: 30415298

Group type: EXPERIMENTAL
Intervention: Tiotropium 18 µg once daily with theophylline 100 mg twice daily (Group I)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Tiotropium 18 µg once daily (Group II)
Number of subjects: 170
Study: 27496687

Group type: EXPERIMENTAL
Intervention: Prenatal surgery
Number of subjects: 183

Group type: COMPARATOR
Intervention: Postnatal surgery
Number of subjects: 183
Study: 24934893

Group type: EXPERIMENTAL
Intervention: G-CSF (10 μg/kg daily for 4 days)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: G-CSF
Number of subjects: 86
Study: 22211448

Group type: EXPERIMENTAL
Intervention: Ganganagar clay dust aerosol
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Bikaner sand dust aerosol
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Jaipur sand dust aerosol
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ganganagar sand dust aerosol
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 21122501

Group type: EXPERIMENTAL
Intervention: Patient Support Program (PSP)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 81
Study: 18005144

Group type: EXPERIMENTAL
Intervention: rizatriptan 10 mg
Number of subjects: 94

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 94
Study: 15877874

Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MD)
Number of subjects: 0
Study: 12889506

Group type: EXPERIMENTAL
Intervention: Fortrans
Number of subjects: 94

Group type: COMPARATOR
Intervention: bisacodyl
Number of subjects: 94
Study: 9179834

Group type: EXPERIMENTAL
Intervention: Electronic information system (voice-interactive, physician-directed, 24h access via touch-tone telephone)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Control group (patients not actively using the system)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Electronic information system
Number of subjects: 204
Study: 1662119

Group type: EXPERIMENTAL
Intervention: Didemnin B at doses ranging from 3.47 to 9.1 mg/m2
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Didemnin B at a recommended dose of 6.3 mg/m2
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Combination of antiemetics including dexamethasone
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Corticosteroids added to premedication regimen
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Didemnin B
Number of subjects: 30
Study: 7073046

Group type: EXPERIMENTAL
Intervention: Oxacillin 500 mg QID x 5 days
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 30501480

Group type: EXPERIMENTAL
Intervention: Guided reflection educational session
Number of subjects: 62

Group type: COMPARATOR
Intervention: Usual care (Control Group)
Number of subjects: 62
Study: 30830377

Group type: EXPERIMENTAL
Intervention: 1,5-anhydroglucitol
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: norvaline
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: L-aspartic acid
Number of subjects: 56
Study: 26884590

Group type: EXPERIMENTAL
Intervention: Sorafenib (S) 800 mg daily
Number of subjects: 106

Group type: COMPARATOR
Intervention: Sorafenib + Everolimus (S + E) 800 mg + 5 mg daily
Number of subjects: 106
Study: 24345385

Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stents (EES)
Number of subjects: 6524

Group type: COMPARATOR
Intervention: Sirolimus-eluting stents (SES)
Number of subjects: 6524

Group type: EXPERIMENTAL
Intervention: Insulin-dependent diabetes
Number of subjects: 6524
Study: 21988149

Group type: EXPERIMENTAL
Intervention: Fenoprofen Calcium (200 mg) in three-layered gum tablet (1800 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lyophilized ternary complex containing 100 mg of Fn with PVP K(25)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fenoprofen Calcium (100 mg) in chewing gum
Number of subjects: 0

Group type: COMPARATOR
Intervention: Selected gum tablet
Number of subjects: 0
Study: 19395079

Group type: EXPERIMENTAL
Intervention: Voglibose 0.2 mg three times a day (n=897)
Number of subjects: 1780

Group type: COMPARATOR
Intervention: Placebo (n=883)
Number of subjects: 1780
Study: 17175181

Group type: EXPERIMENTAL
Intervention: Raloxifene treatment
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 20
Study: 15892043

Group type: EXPERIMENTAL
Intervention: Capecitabine plus docetaxel (1250 mg/m2 twice daily on Days 1-14 plus docetaxel 75 mg/m2 on Day 1)
Number of subjects: 511

Group type: COMPARATOR
Intervention: Docetaxel alone (100 mg/m2 on Day 1)
Number of subjects: 511

Group type: EXPERIMENTAL
Intervention: Capecitabine plus docetaxel
Number of subjects: 511

Group type: COMPARATOR
Intervention: Docetaxel alone
Number of subjects: 511
Study: 11845111

Group type: EXPERIMENTAL
Intervention: Non-hormone replacement therapy (nonHRT) alternatives
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hormone replacement therapy (HRT)
Number of subjects: 0
Study: 10521198

Group type: EXPERIMENTAL
Intervention: Eradication of H pylori
Number of subjects: 0

Group type: COMPARATOR
Intervention: H pylori infection
Number of subjects: 0
Study: 8954445

Group type: EXPERIMENTAL
Intervention: Case managed
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-case managed
Number of subjects: 0
Study: 1833122

Group type: EXPERIMENTAL
Intervention: four‐point profiles on 2 days per week
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: four‐point profiles on 1 day per week
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: two‐point profiles on every day of the week
Number of subjects: 25
Study: 6343726

Group type: EXPERIMENTAL
Intervention: DES plus Cytoxan
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: DES plus Emcyt
Number of subjects: 188

Group type: COMPARATOR
Intervention: DES alone
Number of subjects: 188

Group type: COMPARATOR
Intervention: DES/ORCH
Number of subjects: 188
Study: 31178278

Group type: EXPERIMENTAL
Intervention: Prophylactic intra-aortic balloon counterpulsation (IABC)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (no IABC)
Number of subjects: 24
Study: 24726159

Group type: EXPERIMENTAL
Intervention: Mitomycin-C (MMC) 0.02% applied for 15 seconds
Number of subjects: 60

Group type: COMPARATOR
Intervention: Balanced salt solution applied for 15 seconds (Control)
Number of subjects: 60
Study: 23264316

Group type: EXPERIMENTAL
Intervention: Oxymorphone ER (20 mg)
Number of subjects: 0
Study: 20938423

Group type: EXPERIMENTAL
Intervention: Klamath algae extract (Klamin®, 1600 g/day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (vanilla tablets)
Number of subjects: 30
Study: 18794413

Group type: EXPERIMENTAL
Intervention: Fibrin sealant (human) (Evicel) applied to one side during rhinoplasty
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control side (untreated)
Number of subjects: 10
Study: 16172704

Group type: EXPERIMENTAL
Intervention: Modified Mini-Mental State Examination (mo‐MMSE)
Number of subjects: 253

Group type: COMPARATOR
Intervention: Adapted Mini-Mental State Examination (ad‐MMSE)
Number of subjects: 253
Study: 12376581

Group type: EXPERIMENTAL
Intervention: rosiglitazone (8 mg/day, 2 divided doses)
Number of subjects: 33

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 33
Study: 9456163

Group type: EXPERIMENTAL
Intervention: Isradipine (calcium channel blocker)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Both treatments (Isradipine and Placebo)
Number of subjects: 12
Study: 8582071

Group type: EXPERIMENTAL
Intervention: Bilateral cannulated Merocel nasal packs
Number of subjects: 40

Group type: COMPARATOR
Intervention: Non-cannulated Merocel nasal packs (Control)
Number of subjects: 40
Study: 2930448

Group type: EXPERIMENTAL
Intervention: Safety-signal technique (travelling towards the therapist in fear-inducing situations)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional therapist-assisted exposure
Number of subjects: 0
Study: 1013850

Group type: EXPERIMENTAL
Intervention: Hexoprenaline
Number of subjects: 10

Group type: COMPARATOR
Intervention: Fenoterol
Number of subjects: 10

Group type: COMPARATOR
Intervention: Ritodrine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Salbutamol
Number of subjects: 10

Group type: COMPARATOR
Intervention: All drugs
Number of subjects: 10
Study: 30910569

Group type: EXPERIMENTAL
Intervention: Massage therapy (10 minutes to the quadriceps)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Sham joint mobilisation (control group)
Number of subjects: 78
Study: 28555198

Group type: EXPERIMENTAL
Intervention: Simultaneous walking and isometric handgrip exercise (WHG)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Walking (WLK)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Isometric handgrip exercise (IHG)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 48
Study: 25698076

Group type: EXPERIMENTAL
Intervention: Equine-assisted learning (EAL) for 5 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual (Control)
Number of subjects: 0
Study: 24062815

Group type: EXPERIMENTAL
Intervention: Elaborate feedback and audience response system (ARS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no elaborate feedback)
Number of subjects: 0
Study: 21592127

Group type: COMPARATOR
Intervention: Michigan Model for Health (MMH) curriculum, 24 lessons in grade 4 over 12 weeks and 28 lessons in grade 5 over 14 weeks, taught by trained teachers.
Number of subjects: 2512

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 2512
Study: 19630553

Group type: EXPERIMENTAL
Intervention: Nurse Caring (NC) - three counseling sessions
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: All three interventions (NC, SC, CC)
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: Nurse Caring (NC) and Combined Caring (CC)
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: Nurse Caring (NC) and Self-Caring (SC)
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: Nurse Caring (NC), Combined Caring (CC), and Control
Number of subjects: 341

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 341
Study: 17016841

Group type: EXPERIMENTAL
Intervention: 2 g/kg glucose feed
Number of subjects: 0

Group type: COMPARATOR
Intervention: Water feed (Control)
Number of subjects: 0
Study: 14626626

Group type: EXPERIMENTAL
Intervention: B-vitamin treatment (combination of vitamins B6, B12, and folic acid)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 11061656

Group type: EXPERIMENTAL
Intervention: Hydroxyurea (HU) in combination with stavudine and didanosine
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Didanosine/stavudine/HU
Number of subjects: 102

Group type: COMPARATOR
Intervention: Hydroxyurea (HU)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Stavudine plus didanosine
Number of subjects: 102
Study: 9557073

Group type: EXPERIMENTAL
Intervention: Patients with systemic sclerosis (SSc) with normal thyroid function
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Patients with systemic sclerosis (SSc) with overt or latent hypothyroidism
Number of subjects: 21

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 21
Study: 8168532

Group type: EXPERIMENTAL
Intervention: HsmtSSB protein
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mutated HsmtSSB (Trp68 replaced by threonine and tyrosine)
Number of subjects: 0
Study: 3128572

Group type: EXPERIMENTAL
Intervention: 50 mg natural progesterone i.m. daily from the day of oocyte retrieval onwards
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Natural progesterone in combination with oestradiol valerate
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: HCG supplements
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Endometrial biopsies from patients who did not undergo embryo replacement
Number of subjects: 168
Study: 31477371

Group type: EXPERIMENTAL
Intervention: High Risk Social Challenge Task (HiSoC)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Healthy Controls (HC)
Number of subjects: 102
Study: 29606522

Group type: EXPERIMENTAL
Intervention: Concurrent and adjuvant temozolomide chemotherapy
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Unacceptable variations
Number of subjects: 62
Study: 28138828

Group type: EXPERIMENTAL
Intervention: Docetaxel combined with resminostat (DR) therapy
Number of subjects: 117

Group type: COMPARATOR
Intervention: Docetaxel alone
Number of subjects: 117
Study: 26427307

Group type: EXPERIMENTAL
Intervention: Ultrasound guidance alone (Group A)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Ultrasound with nerve stimulation guidance (Group B)
Number of subjects: 50
Study: 23592678

Group type: EXPERIMENTAL
Intervention: 400 kcal/session exercise
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: 600 kcal/session exercise
Number of subjects: 141

Group type: COMPARATOR
Intervention: Non-exercise control
Number of subjects: 141
Study: 21291506

Group type: EXPERIMENTAL
Intervention: Early ECV (34(0/7) to 35(6/7) weeks of gestation)
Number of subjects: 1543

Group type: COMPARATOR
Intervention: Delayed ECV (at or after 37(0/7) weeks of gestation)
Number of subjects: 1543
Study: 19242711

Group type: EXPERIMENTAL
Intervention: Modified radiofrequency-assisted uvulopalatoplasty (MRAUP)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Radiofrequency-assisted uvulopalatoplasty (RAUP)
Number of subjects: 60
Study: 16480565

Group type: EXPERIMENTAL
Intervention: Cognitive-behaviour therapy group programme for social phobia (10 sessions)
Number of subjects: 112
Study: 15615549

Group type: EXPERIMENTAL
Intervention: Endovascular brachytherapy (EVBT)
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: Probucol (1 g/d)
Number of subjects: 335
Study: 11451263

Group type: EXPERIMENTAL
Intervention: Symptom-limited treadmill tests at one year after CR
Number of subjects: 1678

Group type: EXPERIMENTAL
Intervention: Symptom-limited treadmill tests at three years after CR
Number of subjects: 1678

Group type: EXPERIMENTAL
Intervention: Symptom-limited treadmill tests at five years after CR
Number of subjects: 1678

Group type: EXPERIMENTAL
Intervention: Exercise to Bruce stage 3 or Duke score >-6 at five years
Number of subjects: 1678

Group type: EXPERIMENTAL
Intervention: ST depression on the one-year test
Number of subjects: 1678
Study: 9407641

Group type: EXPERIMENTAL
Intervention: Autologous blood transfusion
Number of subjects: 26

Group type: COMPARATOR
Intervention: Allogeneic blood transfusion
Number of subjects: 26
Study: 7971126

Group type: EXPERIMENTAL
Intervention: Alcohol (95% grain alcohol; mean estimated blood alcohol level = .088%)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Alcohol placebo
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sober condition
Number of subjects: 12
Study: 2885202

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Oxprenolol
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 31638843

Group type: EXPERIMENTAL
Intervention: Topical betamethasone 0.1%
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Topical nepafenac 0.1%
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (no anti-inflammatory agent)
Number of subjects: 90
Study: 28748705

Group type: EXPERIMENTAL
Intervention: Sensor-augmented pumping (SAP) in the STAR 3 trial
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sensor-integrated pumping with low-glucose threshold suspend (SIP+TS) in the ASPIRE In-Home trial
Number of subjects: 0
Study: 27387954

Group type: EXPERIMENTAL
Intervention: Caregiver intervention targeting national fundamental values, consisting of eight guided face-to-face seminars.
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 80
Study: 24656944

Group type: EXPERIMENTAL
Intervention: Nasal spray formulation containing 0.2% sodium hyaluronate and 3% tobramycin
Number of subjects: 27

Group type: COMPARATOR
Intervention: Nasal spray formulation containing 0.2% sodium hyaluronate alone
Number of subjects: 27
Study: 23026255

Group type: COMPARATOR
Intervention: 2-D navigation (group A)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: 3-D navigation (group B)
Number of subjects: 34
Study: 21061762

Group type: EXPERIMENTAL
Intervention: Adapalene-BPO (adapalene 0.1% and benzoyl peroxide 2.5%)
Number of subjects: 2453
Study: 18294813

Group type: EXPERIMENTAL
Intervention: Perceived failure to attain personal goals
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Menstrual dysfunction
Number of subjects: 0